Medtronic Cardiac Surgery launches VitalFlow™ Extracorporeal Membrane Oxygenation (ECMO) system in Europe, advancing care for critically ill patients

Medtronic Cardiac Surgery today announced the European launch of its Extracorporeal Membrane Oxygenation (ECMO) system called the VitalFlow™ system, a configurable one-system ECMO solution, built on simplicity and performance. The VitalFlow™ ECMO system bridges the gap between bedside care and intra-hospital transport, offering physicians and clinicians a simple, fully integrated ECMO portfolio, purpose-built to meet the complex and evolving demands of modern intensive care units. Medtronic's Cardiac Surgery team will launch the VitalFlow system in Europe at the 39^th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting from October 8-11 in Copenhagen, Denmark.

The VitalFlow system technology, which first launched in the United States in September 2024, is the most innovative technology to-date from the Medtronic acquisition of MC3 Cardiopulmonary, which closed in March 2024. The acquisition marked the culmination of an eight-year partnership and distribution agreement with the Medtronic Cardiac Surgery business resulting in the introduction of seven new ECMO products in seven years.

"The VitalFlow ECMO system is more than a system - it represents a step forward in transforming how ECMO is delivered across Europe, supporting care teams in providing support to critically ill patients and contributing to advancing patient care," said Giuseppe Savoja, Western Europe senior business director for the Cardiac Surgery business, which is part of the Cardiovascular Portfolio at Medtronic. "Medtronic offers the most comprehensive Cardiac Surgery portfolio available today. This launch underscores Medtronic's commitment to advancing life-restoring medical technologies that address acute cardiopulmonary needs, and it reinforces our dedication to this critical field."

The VitalFlow system brings a critical solution for ECMO
The user-friendly VitalFlow system features a large, intuitive touch screen that centralizes real-time performance data, offers configurability, and is built for acute cardiopulmonary needs and long-term performance, incorporating the previously launched Medtronic Nautilus™ ECMO oxygenator design.

"We gathered feedback from hundreds of clinicians with diverse ECMO specialties, and we were able to design the VitalFlow system to address the most pressing unmet needs of simplicity, configurability and performance in an ECMO system," said Savoja. "The simplicity of the VitalFlow system allows clinicians to serve patients confidently and efficiently. It is easily portable from various departments within the hospital setting and designed for durability and performance."

Medtronic's Cardiac Surgery team recently introduced the ECMObile - a mobile simulation and education unit designed to offer immersive, hands-on ECMO training. Over the next 12 months, it will travel across Europe, facilitating direct engagement with healthcare professionals to educate on best practices in ECMO management.

"As patient complexity grows, so do the evolving needs of clinicians in the ECMO space," said Pieter Kappetein, Ph.D., M.D., chief medical officer for Cardiac Surgery at Medtronic. "This is driving demand for innovative solutions across multiple disease areas, and Medtronic is well positioned to meet those needs by advancing treatment options that better support patients."

About ECMO
ECMO uses a pump and oxygenator outside of the body to take over the work of the heart and lungs to restore health and extend life to critically ill patients in a hospital setting who might otherwise expire. ECMO is most often used for life-threatening heart or lung failure to allow the heart and/or lung to rest and heal. It's also used as a bridge option to heart or lung transplantation or to further treatment such as heart assist device or left ventricular assist device (LVAD).

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

María Trenzado
Communications
Medtronic Western Europe
+34 653 30 47 20

Becky Dvorak
Public Relations
+1-612-309-7149

Ryan Weispfenning
Investor Relations
+1-763-505-4626